Skip to content
2000
Volume 4, Issue 1
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

Epithelial ovarian cancer is the most lethal of gynecologic malignancies in the United States and while current therapies are successful for many years, cure remains elusive. Angiogenesis is the physiological process of new blood vessel growth, and a normal process in growth, development, and wound healing. However, angiogenesis is also a fundamental step in the transition of tumors from a dormant state to a malignant state. Preclinical data and preliminary clinical data suggest that antiangiogenic therapy targeting the vascular endothelial growth factor (VEGF) pathway will change the natural history of epithelial ovarian cancer. With a proven survival advantage in a growing number of tumor types, antiangiogenenic therapy is an exciting field. Important questions remain: the mechanism of activity, optimal integration with chemotherapy, and the benefits and risks of targeting multiple pathways, these are being addressed through a series of clinical trials, designed to evaluate the tumor microenvironment and surrogate endpoints, such as wound healing, leading to a more rationale triaging of patients to this potentially dangerous and costly therapy. The scientific background, and clinical trials with novel agents are reviewed in this exciting new paradigm of care.

Loading

Article metrics loading...

/content/journals/cwhr/10.2174/157340408783572079
2008-02-01
2025-05-24
Loading full text...

Full text loading...

/content/journals/cwhr/10.2174/157340408783572079
Loading

  • Article Type:
    Research Article
Keyword(s): Bevacizumab; Cisplatin; PET scans; Sorafenib; Vascular Endothelial Growth Factor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test